Two bills would enact protections for Virginia medical cannabis patients’ employment status.
In mid-February 2024, two bills, House Bill 149 and Senate Bill 391, recently passed, both aiming to provide protections for employees in the public sector, such as teachers or police officers, who use medical cannabis (1). In Virginia, patients seeking medical cannabis must obtain authorization from an approved practitioner and can only purchase their medication through the state’s program (1).
The summary of the intent of House Bill 149 read (2): “Amends the provision that prohibits an employer from discriminating against an employee for such employee's lawful use of cannabis product pursuant to a valid written certification issued by a practitioner for the treatment or to eliminate the symptoms of the employee's diagnosed condition or disease, with certain exceptions, by specifying that such use must conform to the laws of the Commonwealth and that such protections extend to the employees of the Commonwealth and other public bodies.”
In short, patients would potentially no longer risk their jobs by taking their medication. Employers would still be able to impose on-the-clock cannabis use restrictions and reprimands for impairment, though an accurate measurement for impairment has yet to be fully established (1,3).
HB 149 passed with a vote of 78–20 (1). It was sponsored by Delegate Dan Helmer, who also sponsored a bill several years ago that established protections for employees in the private sector (1). “The key was we left our brave first responders out of this,” Helmer said (1). “That was never our intent and so this bill is meant to fix that.”
Supporters of the bill testified that medical cannabis use had a positive effects, such as less alcohol and opioid use (1).
Senate Bill 391, which recently passed in a 30–10 vote, is similar to HB 149, though it excludes police officers (3). Both bills are now in the House and Senate, respectively (1).
References
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.